Acinetobacter Infections - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Acinetobacter Infections - Pipeline Review, H2 2018’, provides an overview of the Acinetobacter Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acinetobacter Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acinetobacter Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acinetobacter Infections

- The report reviews pipeline therapeutics for Acinetobacter Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Acinetobacter Infections therapeutics and enlists all their major and minor projects

- The report assesses Acinetobacter Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Acinetobacter Infections

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Acinetobacter Infections

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Acinetobacter Infections pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

ABAC Therapeutics SA

Achaogen Inc

Acies Bio doo

AiCuris GmbH & Co KG

AmpliPhi Biosciences Corp

Appili Therapeutics Inc

Aridis Pharmaceuticals Inc

AstraZeneca Plc

Atterx ...

ABAC Therapeutics SA

Achaogen Inc

Acies Bio doo

AiCuris GmbH & Co KG

AmpliPhi Biosciences Corp

Appili Therapeutics Inc

Aridis Pharmaceuticals Inc

AstraZeneca Plc

Atterx Biotherapeutics Inc

C3J Therapeutics Inc

ContraFect Corp

Destiny Pharma Plc

Entasis Therapeutics Inc

F. Hoffmann-La Roche Ltd

Hsiri Therapeutics LLC

KBP BioSciences Co Ltd

LegoChem Biosciences Inc

Meiji Seika Pharma Co Ltd

Melinta Therapeutics Inc

Novabiotics Ltd

Octagon Therapeutics Inc

Oxford Drug Design Ltd

Peptilogics Inc

Pfizer Inc

Redx Pharma Plc

Sealife PHARMA GMBH

Shionogi & Co Ltd

Spero Therapeutics Inc

Summit Therapeutics Plc

Techulon Inc

Tetraphase Pharmaceuticals Inc

Vaxdyn SL

Venus Medicine Research Center

Xellia Pharmaceuticals ApS

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Acinetobacter Infections – Overview 6

Acinetobacter Infections – Therapeutics Development 7

Acinetobacter Infections – Therapeutics Assessment 18

Acinetobacter Infections ...

Table of Contents

Table of Contents 2

Introduction 5

Acinetobacter Infections – Overview 6

Acinetobacter Infections – Therapeutics Development 7

Acinetobacter Infections – Therapeutics Assessment 18

Acinetobacter Infections – Companies Involved in Therapeutics Development 26

Acinetobacter Infections – Drug Profiles 41

Acinetobacter Infections – Dormant Projects 142

Acinetobacter Infections – Discontinued Products 144

Acinetobacter Infections – Product Development Milestones 145

Appendix 160

List of Tables

List of Tables

Number of Products under Development for Acinetobacter Infections, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products ...

List of Tables

Number of Products under Development for Acinetobacter Infections, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Acinetobacter Infections – Pipeline by ABAC Therapeutics SA, H2 2018

Acinetobacter Infections – Pipeline by Achaogen Inc, H2 2018

Acinetobacter Infections – Pipeline by Acies Bio doo, H2 2018

Acinetobacter Infections – Pipeline by AiCuris GmbH & Co KG, H2 2018

Acinetobacter Infections – Pipeline by AmpliPhi Biosciences Corp, H2 2018

Acinetobacter Infections – Pipeline by Appili Therapeutics Inc, H2 2018

Acinetobacter Infections – Pipeline by Aridis Pharmaceuticals Inc, H2 2018

Acinetobacter Infections – Pipeline by AstraZeneca Plc, H2 2018

Acinetobacter Infections – Pipeline by Atterx Biotherapeutics Inc, H2 2018

Acinetobacter Infections – Pipeline by C3J Therapeutics Inc, H2 2018

Acinetobacter Infections – Pipeline by ContraFect Corp, H2 2018

Acinetobacter Infections – Pipeline by Destiny Pharma Plc, H2 2018

Acinetobacter Infections – Pipeline by Entasis Therapeutics Inc, H2 2018

Acinetobacter Infections – Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Acinetobacter Infections – Pipeline by Hsiri Therapeutics LLC, H2 2018

Acinetobacter Infections – Pipeline by KBP BioSciences Co Ltd, H2 2018

Acinetobacter Infections – Pipeline by LegoChem Biosciences Inc, H2 2018

Acinetobacter Infections – Pipeline by Meiji Seika Pharma Co Ltd, H2 2018

Acinetobacter Infections – Pipeline by Melinta Therapeutics Inc, H2 2018

Acinetobacter Infections – Pipeline by Novabiotics Ltd, H2 2018

Acinetobacter Infections – Pipeline by Octagon Therapeutics Inc, H2 2018

Acinetobacter Infections – Pipeline by Oxford Drug Design Ltd, H2 2018

Acinetobacter Infections – Pipeline by Peptilogics Inc, H2 2018

Acinetobacter Infections – Pipeline by Pfizer Inc, H2 2018

Acinetobacter Infections – Pipeline by Redx Pharma Plc, H2 2018

Acinetobacter Infections – Pipeline by Sealife PHARMA GMBH, H2 2018

Acinetobacter Infections – Pipeline by Shionogi & Co Ltd, H2 2018

Acinetobacter Infections – Pipeline by Spero Therapeutics Inc, H2 2018

Acinetobacter Infections – Pipeline by Summit Therapeutics Plc, H2 2018

Acinetobacter Infections – Pipeline by Techulon Inc, H2 2018

Acinetobacter Infections – Pipeline by Tetraphase Pharmaceuticals Inc, H2 2018

Acinetobacter Infections – Pipeline by Vaxdyn SL, H2 2018

Acinetobacter Infections – Pipeline by Venus Medicine Research Center, H2 2018

Acinetobacter Infections – Pipeline by Xellia Pharmaceuticals ApS, H2 2018

Acinetobacter Infections – Dormant Projects, H2 2018

List of Figures

List of Figures

Number of Products under Development for Acinetobacter Infections, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products ...

List of Figures

Number of Products under Development for Acinetobacter Infections, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports